Press releases

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility

A live webcast and replay of the March 15th session will be available. Learn how to tune in.

Trial is designed to analyze "real-world" outcomes for patients with gastroesophageal reflux disease (GERD).

Johnson & Johnson trial results add to the extensive body of clinical evidence reinforcing the safety profile of Company’s TAXUS system.

Nine-month study data presented at the annual American College of Cardiology scientific session in Orlando.

(March 4, 2005) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has completed its acquisition of Advanced Stent Technologies, Inc. (AST) of Pleasanton, California, for an...

(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs...

TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

Announcement confirms the safety and efficacy of coil embolization for the treatment of ruptured and unruptured brain aneurysms.

A live webcast and replay of the Feb. 8th session will be available. Learn how to tune in for the presentation.

At a meeting with analysts and investors, Company provided ranges for both sales and earnings goals for the three-year period.

Next-generation stent system has been launched in 18 countries.

On February 1, Company will provide financial guidance for 2005, and financial goals for 2006 and 2007. Learn how to tune in.

A live webcast and replay of the January 25th session will be available. Learn how to tune in for the presentation.

Marks a major milestone for the Company and for the treatment of coronary artery disease.

Launch of TAXUS™ Liberté™ paclitaxel-eluting coronary stent system in 18 countries provides physicians state-of-the-art drug-eluting stent technology for the treatment of coronary artery disease.

The announcement was made by Jim Tobin, President and Chief Executive Officer, at the JPMorgan Healthcare Conference in San Francisco.

U.S. District Court in Delaware granted summary judgment of non-infringement in favor of Boston Scientific.

A live webcast and replay of the January 10th session will be available. Learn how to tune in for the presentation.

Jim Tobin, President and CEO, calls Company’s 2004 performance “nothing short of remarkable and speaks to a truly global effort."

Money is being directed to the Red Cross' International Response Fund.

Expansion of management structure is designed to position the Company for continued growth and success.

The transaction is expected to close early next year.

Motions for summary judgment were granted in part and denied in part.

A live webcast and replay of the December 1 conference session will be available.

An existing licensing agreement with Angiotech Pharmaceuticals, Inc. allows Company to obtain an exclusive license for the use of paclitaxel and other agents in the coronary vascular field.

French government adds new patient categories to reimbursement approval criteria.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Equity investment in a privately held company developing a balloon-expandable, bioresorbable drug-eluting stent.

The two series of senior notes will have varied maturities and a combined aggregate principal amount of $500 million.

A live webcast and replay of the November 18 conference session will be available.

Company subsidiary will resume worldwide distribution after a voluntary recall of all unimplanted cochlear implant systems.

TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations.

A live webcast and replay of the November 10 conference session will be available.

Patients with Gastroesophageal Reflux Disease (GERD) reported substantial improvements after the Enteryx® Procedure.

and Orlando, FL (November 2, 2004)-- Boston Scientific Corporation (NYSE: BSX) today announced results supporting the efficacy of the Enteryx Procedure in relieving the symptoms of...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of...

Innovative uterine fibroid embolization (UFE) procedure is a less-invasive treatment option for fibroids.

Full line of mid-urethral sling products for the treatment of female stress urinary incontinence.

ARRIVE 2 registry program plans to enroll 5,000 patients at approximately 60 centers in the United States.

Repurchased shares will be made available for issuance under the Company's equity incentive plans and for general corporate purposes.

“This quarter was one of the best performances in our history," said Jim Tobin, President and CEO.

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.

Benefits reported at 12 months were maintained at two years.

The data demonstrated that the safety and efficacy benefits associated with the TAXUS stent system were maintained at two years.

Company will make a special one-time contribution to its U.S. 401(k) Retirement Savings Plan and increase match amounts to six percent of pay.

Subsidiary Advanced Bionics Corporation is voluntarily recalling worldwide all unimplanted CLARION® and HiResolution® cochlear implants.

Together, studies presented will represent more than 10,000 patients.

Galway facility is one of two Company facilities that manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately $200 million.

Registry designed to assess physician usage patterns and evaluate outcome data in "real world" patients.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast a conference call providing updates on its business performance for 2004 and sales of its TAXUS™ Express2™...

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...

(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...

(August 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2...

(August 10, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made a significant equity investment in Northstar Neuroscience, Inc., a privately held company located in...

(August 5, 2004)

(July 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2004. Net sales for the second quarter were $1.460 billion as...

(July 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its...

(July 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 26, at 9:00...

(July 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS™ Express2™...

(July 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its clinical trial known as FLAME. This prospective, multi-center, randomized study will...

(July 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is voluntarily recalling nationwide approximately 200 units of its TAXUS™ Express2™ Paclitaxel-Eluting...

(June 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 19, at 9:00...

(June 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of its public offering of $600 million aggregate principal amount of 5.45 percent Senior Notes due June...

(June 22, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of $500 million aggregate principal amount of senior notes, under the Company's existing...

(June 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 25th Annual Healthcare Conference, which is being held June 7-10 in Dana Point, CA. Larry...

(June 3, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the...

and Valencia, California (June 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) and Advanced Bionics Corporation, a privately held company located in Valencia, CA, today announced the...

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

and Paris (May 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites...

and Paris (May 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe,...

(May 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment in ARRIVE, a peri-approval registry. ARRIVE was designed to collect and analyze...

(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the...

and New Orleans, LA (May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced sub-population data from a 12-month, 117-patient study of the Enteryx procedure for patients...

and New Orleans, LA (May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced clinical trial data supporting the safety and effectiveness of the Enteryx procedure in relieving...

(May 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Banc of America Securities Health Care Conference 2004, which is being held May 19-21 in Las Vegas....

(May 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(April 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being held May 5-7 in Miami. On...

(April 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its clinical trial to evaluate the benefits of stenting in conjunction with embolic protection...

(April 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its first quarter ended March 31, 2004, as well as preliminary information related to U.S. sales...

(April 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Express® Biliary...

(April 14, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2004 on Tuesday, April 20, at 9:00...

(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by...

(April 7, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West...

(April 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary results related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system and...

(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston...

(March 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has concluded enrollment in its TAXUS V de novo lesion clinical trial. The Company has enrolled 1,172...

(March 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Contour SE™...

(March 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) and EndoTex Interventional Systems, Inc. announced today the completion of enrollment in a carotid artery stenting clinical trial to...

(March 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system....

(December 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all Stainless Steel Greenfield® Vena Cava Filters with 12Fr Femoral Introducer...

(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS™ Express2™...